摘要
目的探讨紫杉醇(PTX)为主的联合化疗方案治疗晚期乳腺癌的疗效及安全性。方法40例晚期乳腺癌患者中,19例既往未用过蒽环类治疗,予PTX联合阿霉素治疗;21例既往用过蒽环类治疗失败,予PTX联合顺铂治疗。21天为1周期,2周期后评价疗效,有效者化疗4周期以上。结果40例中治疗后完全缓解7例,部分缓解20例,稳定9例,进展4例,有效率67.5%(27/40);主要不良反应为白细胞减少,发生率为87.5%,其中III-IV度占40%。结论PTX为主的联合化疗方案治疗晚期乳腺癌疗效确切,不良反应可耐受。
Objective To explore paclitaxel （PTX） union chemotherapy curative effect and security for breast cancer of later period. Methods Among 40 later period breast cancer patients 21 cases were given PTX plus amycine,21 cases were given PTX and cisplatin,21 days are a cycle, the curative effect were evaluated, after 4 cycles of chemotherapy. Results Among 40 cases, CR 7 cases, PR 20 caese, Steady 9 ,Develop 4, Efficient rate 67.5% （27/40）. The main poisonous side effect are reduced the leucocyte, the incidence is 87. 5%, among them Ⅲ- Ⅳ degree accounts for 40%. Conclusion PTX treats the breast cancer of later period with the union chemotherapy scheme is effective, The poisonous side reaction can be tolerable.
出处
《医药论坛杂志》
2007年第5期16-17,共2页
Journal of Medical Forum
关键词
紫杉醇
乳腺癌
化疗
Paclitaxel
Breast cancer
Chemotherapy
